|
Each tablet contains :
Composition:
Mycophenolate Mofetil
...................................................500
mg
Indications:
Mycophenolate is indicated for the
prophylaxis of organ rejection in
patients receiving allogeneic renal,
cardiac or hepatic transplants.
Mycophenolate should be used
concomitantly with cyclosporine and
corticosteroids.
Description:
The salvage pathway of purine synthesis
in lymphocytes is less active than the
de novo synthesis of purines. Inosine
monophosphate is converted to guanosine
monophosphate by inosine monophosphate
dehydrogenase. During T-cell activation,
the activity of both types I and II
inosine monophosphate dehydrogenase
enzymes increases by tenfold.
Mycophenolate mofetil is converted in
the liver by ester hydrolysis to
mycophenolic acid, which in turn
non-competitively and reversibly
inhibits types I and II inosine
monophosphate dehydrogenase activity
during DNA synthesis in the S phase of
the cell cycle. In the salvage pathway,
guanine is converted to guanine
monophosphate by the enzyme
hypoxanthine-guanine
phosphoribosyltransferase.
Dosage :
A dose of 1 g administered orally twice
a day (daily dose of 2 g) is recommended
for use in renal transplant patients or
as per the physician’s advice.
Presentations:
10 tablets
MRP Retailer Stockist
880.00 704.00 633.60
|
